Welcome, Guest. Please login or register.
December 07, 2016, 02:52:37 PM

Login with username, password and session length

  • Total Members: 29683
  • Latest: DeanoR
  • Total Posts: 704585
  • Total Topics: 56091
  • Online Today: 252
  • Online Ever: 1421
  • (August 13, 2016, 05:18:44 AM)
Users Online
Users: 6
Guests: 157
Total: 163


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Radioimmunotherapy clears HIV-infected cells in mice  (Read 1546 times)

0 Members and 1 Guest are viewing this topic.

Offline manchesteruk

  • Member
  • Posts: 631
Radioimmunotherapy clears HIV-infected cells in mice
« on: November 08, 2006, 06:11:46 PM »
If i'm being honest this article confuses me I was hoping someone might be able to explain it cough matt cough.


 Attaching radioactive particles to antibodies that target HIV envelope proteins resulted in clearance of more than 99% of HIV-infected cells from the spleens of immunodeficient mice, researchers from the US and Germany report in an article released this week by PloS Medicine. Radioimmunotherapy may have the potential to eradicate hard-to-clear HIV-infected cells from the body without serious toxicity, the researchers suggest.

Radioimmunotherapy using monoclonal antibodies tagged with isotopes is already used successfully in cancer therapy to eliminate cancerous cells in B-cell non-Hodgkin lymphoma, and has been demonstrated to clear bacterial and fungal infections in proof-of-concept experiments. Radioimmunotherapy may soon be approved as a first-line therapy for some forms of lymphoma.

In HIV infection chronicly infected cells form a reservoir of HIV infection that has proved impossible to eliminate even after long periods of viral suppression using antiretroviral therapy, and scientists have begun to look at other methods of clearing the viral reservoir in the hope that the infection can eventually be eradicated from the body. Chronicly infected cells may also harbour drug-resistant viruses that can provide a reservoir to fuel viral rebound in treatment-experienced patients

This study used monoclonal antibodies to HIVís gp120 and gp41 envelope proteins, tagged with bismuth 213 and rhenium 188 respectively, and tested their relative effectiveness at eliminating HIV-infected white blood cells in the test tube. The white blood cells infected by HIV, lymphocytes, are amongst the cells most sensitive to radiation in the human body, so even a very small dose delivered directly to a lymphocyte is enough to kill it.

The test tube study found that bismuth-linked antibodies were more effective, and that an antibody to the gp41 protein designed to bind to the 246-D region ( a conserved sequence present across a wide range of genetically diverse HIV strains) was highly effective. Importantly, none of the antibodies killed cells in samples that did not contain HIV-infected cells.

Immunodeficient mice that had been infected with HIV were treated with a single dose of the radiolabelled antibody, resulting in a significant reduction in HIV-infected cells of greater than 99%.

Further mouse studies using a thy/liv SCID-hu mouse, engineered to develop thymus tissue that can produce CD4 cells, sought to determine whether infection of thymic tissue could be blocked by radiolabelled antibodies. Treatment with the rhenium-associated gp41 antibody reduced the number of HIV-infected thymoctes by more than 95% when compared to a control treatment lacking a gp41 antibody.

The study also found little or no haematologic toxicity, unlike that seen with radiolabelled antibodies targeting cancerous cells. The authors of the study say this lack of toxicity probably reflects the fact that clearing virally infected cells through targeting of viral proteins displayed on the cell surface allows radioisotopes to be targeted much more specifically, and with much less potential for damage to other host cells.

The authors note that any radioimmunotherapy approach using monoclonal antibodies must be able to out-compete human antibodies against HIV, either by using very high doses of antibodies or by very specific targeting of HIV epitopes by antibodies. They also remark that the approach may be able to clear quiescent HIV-infected cells that have already been stimulated by valproic acid, an agent which has been shown to activate them.


Dadachova E et al. Targeted killing of virally infected cells by radiolabelled antibodies to viral proteins. PloS Medicine 3 (11): e427, 2006.

Diagnosed 11/05

"Life is too important to be taken seriously" Oscar Wilde

Offline newt

  • Member
  • Posts: 3,896
  • the one and original newt
Re: Radioimmunotherapy clears HIV-infected cells in mice
« Reply #1 on: November 08, 2006, 07:13:54 PM »
Basically, this report is saying a study attached radioactive particles to monoclonal (manufactured, identical) antibodies and watched them attack and mostly eliminate the HIV virus in the pancreas of mice, therefore maybe monoclonal antibodies are a strategy to get rid of HIV from the parts of the body HIV drugs don't reach, and, er, more is study needed.

- matt

Now playing: slight voluntary cough cough and Pink Floyd, Any Colour You Like (note correct English spelling for "colour")
"The object is to be a well patient, not a good patient"


Terms of Membership for these forums

© 2016 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.